Open AccessFOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)
Author(s) -
Yukimasa Hatachi,
SHARAD R. MOHAN,
Takeshi Kotake,
Hironaga Satake,
Yoshihiro Okita,
Hisateru Yasui,
Akihito Tsuji
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10083
Subject(s) - folfirinox , irinotecan , oxaliplatin , medicine , fluorouracil , chemotherapy , bolus (digestion) , pancreatic cancer , oncology , gastroenterology , cancer , colorectal cancer
FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.